AR038003A1 - Compuesto de triazolo[4,3-a]pirido(2,3-d)pirimidin-5-ona, composiciones que lo contienen, metodo de preparacion y su uso - Google Patents
Compuesto de triazolo[4,3-a]pirido(2,3-d)pirimidin-5-ona, composiciones que lo contienen, metodo de preparacion y su usoInfo
- Publication number
- AR038003A1 AR038003A1 ARP020104520A ARP020104520A AR038003A1 AR 038003 A1 AR038003 A1 AR 038003A1 AR P020104520 A ARP020104520 A AR P020104520A AR P020104520 A ARP020104520 A AR P020104520A AR 038003 A1 AR038003 A1 AR 038003A1
- Authority
- AR
- Argentina
- Prior art keywords
- chosen
- alkyl
- radicals
- radical
- alkoxy
- Prior art date
Links
- -1 TRIAZOL COMPOUND Chemical class 0.000 title abstract 13
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title 1
- 150000003254 radicals Chemical group 0.000 abstract 14
- 125000000217 alkyl group Chemical group 0.000 abstract 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 9
- 125000003545 alkoxy group Chemical group 0.000 abstract 7
- 125000005842 heteroatom Chemical group 0.000 abstract 5
- 229910052760 oxygen Inorganic materials 0.000 abstract 5
- 229910052717 sulfur Inorganic materials 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 4
- 125000004414 alkyl thio group Chemical group 0.000 abstract 3
- 125000004429 atom Chemical group 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 abstract 2
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 abstract 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 abstract 2
- 125000003396 thiol group Chemical class [H]S* 0.000 abstract 2
- WTYLPQUOPMMOQW-UHFFFAOYSA-N 6h-1,6-naphthyridin-5-one Chemical class C1=CC=C2C(O)=NC=CC2=N1 WTYLPQUOPMMOQW-UHFFFAOYSA-N 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 150000005840 aryl radicals Chemical class 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 229920001577 copolymer Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000003884 phenylalkyl group Chemical group 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Compuestos de triazolo[4,3-a]pirido[2,3-d]piridin-5-ona de fórmula general (1) donde: X representa un radical elegido de H, radicales hidroxilo, halógeno, amino, nitro, mercapto, ciano, o carboxilo, radicales alquilo, alcoxi, alquiltio, alquilsulfinilo o alquilsulfonilo optativamente sustituidos con 1, 2, o 3 átomos de halógeno, los radicales -NR3R4 con R3 y R4, que son idénticos o diferentes, elegidos de los siguientes radicales: H, alquilo optativamente sustituido con 1, 2 o 3 grupos elegidos de halógeno, hidroxilo, ciano y alcoxi, -C(O)R5 con R5 elegido de H o alquilos optativamente sustituidos con un radical hidroxilo, alcoxi, mercapto o alquiltio, -(CH2)x-cicloalquilo optativamente sustituido con un radical hidroxilo, alcoxi, mercapto, alquiltio, amino, alquilamino, N-alquilo, N-alquilamino o alquilo que comprende 1, 2, 3 o 4 átomos de carbono en la forma de una cadena lineal o ramificada, x es un número entero elegido de 0, 1, 2, 3 y 4, o los radicales de la fórmula (2) en donde: n es un número entero elegido de 0 y 1 ,cuando n=1, entonces A representa un átomo de H o un sustituyente CO-Q1-Q2-Q3, Q1 representa un radical oxi (-O-). -NH-, estructura (3), o alternativamente; estructura (4), p y p´ son números enteros, elegidos independientemente uno de otro de 0, 1, 2, y 3 y Z representa un grupo -CH-, -N- o alternativamente oxi, Q2 representa un grupo -(CH2)q-, q es un número entero elegido de 0, 1, 2, 3 y 4, o un grupo -(CH2-CH2-O)r-, r es un número entero elegido de 2, 3 y 4, y Q3 representa un átomo de H o un radical elegido de hidroxilo, metoxi, -O-CO-X1, -NHX2 y -N(X1)X2, X1 y X2, que son idénticos o diferentes, representan un radical alquilo o X1 y X2 están unidos de manera tal que forman, junto con el átomo de N al cual están unidos, un radical azacicloalquilo que comprende 3, 4, 5, 6, 7, 8, 9 o 10 miembros y es capaz además de comprender 1, 2, o 3 heteroátomos elegidos de O, S y/o N, siendo posible que los sustituyentes -CO-Q1-Q2-Q3 sean idénticos o diferentes dentro de la misma unidad de la fórmula [N(A)]n-CO-Q1-Q2-Q3, y los radicales de la fórmula (5) en donde el anillo formado con el átomo de N comprende 3, 4, 5, 6, 7, 8, 9 o 10 miembros y puede, además, comprender 1, 2 o 3 heteroátomos elegidos de O, S y/o N, siendo posible que el anillo también esté unido en puente por un alquilo, para ser gem dialquilado o sustituido con 1, 2, o 3 grupos elegidos de radicales hidroxilo, oxo, alquilo y/o alcoxi o con un grupo -CO-Q1-Q2-Q3 definido anteriormente, R representa un radical elegido de: radicales alquilo, alquenilo, alquinilo, 2-, 3-, o 4- piridilalquilo, siendo posible que dichos piridilos sean optativamente sustituidos una, dos o tres veces con radicales alquilo, alcoxi, hidroxilo, halógeno y/o amino, o los radicales de las fórmulas (6), (7), (8) y (9) en donde: s es un número entero elegido de 1, 2, 3 y 4 Ar representa un radical arilo de 5 o 6 miembros que puede comprender, además 1, 2, 3 o 4 heteroátomos elegidos de O, S y/o N, Y1, Y2 e Y3, que son idénticos o diferentes, son radicales elegidos de H, hidroxilo, mercapto, amino, nitro, halógeno, -C(O)R6, -C(O)OR6, -C(O)NR6R7, -NR6R7, -(CH2)t-CN o -(CH2)t-C(O)-Q1-Q2-Q3, siendo t un número entero elegido de 0, 1, y 2, Q1, Q2, y Q3 son lo definido anteriormente, y R6 y R7, que son idénticos o diferentes, representan H o un radical alquilo o alternativamente R6 y R7 están unidos de manera tal que forman, junto al átomo de N al cual están unidos , un radical azacicloalquilo que comprende 4, 5, 6 o 7 miembros y que puede comprender, además, 1, 2 o 3 heteroátomos elegidos de N, O, y/o S, alquilo, alcoxi, alquiltio, alquilsulfinilo o alquilsulfonilo, estos radicales son optativamente sustituidos con 1, 2 o 3 átomos de halógeno, R1 y R2 representan: radicales alquilo cuando R1 y R2 son idénticos, o alternativamente cuando R1 y R2 son diferentes, radicales alquilo, aralquilo, cicloalquilo o cicloalquilalquilo, alternativamente, R1 y R2 están unidos de manera tal que forman, junto con el átomo de N al cual están unidos, un radical azacicloalquilo que comprende 4, 5, 6 o 7 miembros y que puede comprender, además, 1, 2 o 3 heteroátomos elegidos de O, S, y/o N, siendo posible que dicho anillo así formado sea optativamente unido en puente por un alquilo, para ser gem dialquilado o sustituido con 1, 2 o 3 grupos elegidos de radicales hidroxilo, oxo, alquilo, alcoxi o fenilalquilo y/o un grupo -CO-Q1-Q2-Q3 definido anteriormente, siendo posible que dos de los átomos del anillo mencionado así formado también formen parte de otro anillo elegido de fenilo y heteroarilo que tiene 4, 5, 6, 7 o 8 miembros y que comprende, además 1, 2, 3 o 4 heteroátomos elegidos de O, S y/o N, y sus regioisómeros, sus sales y sus solvatos. Composiciones que los comprenden, métodos de preparación de los mismos y uso para preparar composiciones farmacéuticas. Poseen propiedades que inhiben PDE4 y/o la liberación de TNF?, y pueden usarse para tratamiento o prevención de numerosas condiciones en virtud de la inhibición de la enzima PDE4 y el aumento resultante en el nivel de cAMP:
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0115249A FR2832711B1 (fr) | 2001-11-26 | 2001-11-26 | Derives de triazolo [4,3-a] pyrido [2,3-d] pyrimidin-5-ones, compositions les contenant, procede de preparation et utilisation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR038003A1 true AR038003A1 (es) | 2004-12-22 |
Family
ID=8869777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020104520A AR038003A1 (es) | 2001-11-26 | 2002-11-25 | Compuesto de triazolo[4,3-a]pirido(2,3-d)pirimidin-5-ona, composiciones que lo contienen, metodo de preparacion y su uso |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6787554B2 (es) |
| EP (1) | EP1451190A1 (es) |
| JP (1) | JP2005529843A (es) |
| AR (1) | AR038003A1 (es) |
| AU (1) | AU2002361407A1 (es) |
| BR (1) | BR0214439A (es) |
| CA (1) | CA2468071A1 (es) |
| FR (1) | FR2832711B1 (es) |
| HN (1) | HN2002000327A (es) |
| MX (1) | MXPA04004429A (es) |
| PA (1) | PA8558301A1 (es) |
| PE (1) | PE20030664A1 (es) |
| SV (1) | SV2003001410A (es) |
| TW (1) | TW200300344A (es) |
| UY (1) | UY27546A1 (es) |
| WO (1) | WO2003045951A1 (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ブレインセルス，インコーポレイティド | ムスカリン性受容体調節による神経発生 |
| JP2009512711A (ja) | 2005-10-21 | 2009-03-26 | ブレインセルス，インコーポレイティド | Ｐｄｅ阻害による神経新生の調節 |
| JP2009513672A (ja) | 2005-10-31 | 2009-04-02 | ブレインセルス，インコーポレイティド | 神経発生のｇａｂａ受容体媒介調節 |
| RU2008122978A (ru) | 2005-11-09 | 2009-12-20 | Комбинаторкс, Инкорпорейтед (Us) | Способы, композиции и наборы для лечения медицинских состояний |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| AU2007249399A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| WO2007134077A2 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
| MX2009002496A (es) | 2006-09-08 | 2009-07-10 | Braincells Inc | Combinaciones que contienen un derivado de 4-acilaminopiridina. |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| EP2266985A1 (en) * | 2009-06-26 | 2010-12-29 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Tricyclic Pyrimidine Derivatives as Wnt antagonists |
| US20150119399A1 (en) | 2012-01-10 | 2015-04-30 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
| CN105121439A (zh) | 2013-02-19 | 2015-12-02 | 辉瑞公司 | 作为pde4亚型抑制剂用于治疗cns和其他病症的氮杂苯并咪唑化合物 |
| PL3597649T3 (pl) * | 2014-04-23 | 2022-04-04 | Dart Neuroscience Llc | Kompozycje zawierające podstawione związki [1,2,4]triazolo[1,5-a]pirymidyn-7-ylowe jako inhibitory pde2 |
| JP6713982B2 (ja) | 2014-07-24 | 2020-06-24 | ファイザー・インク | ピラゾロピリミジン化合物 |
| KR102061952B1 (ko) | 2014-08-06 | 2020-01-02 | 화이자 인코포레이티드 | 이미다조피리다진 화합물 |
| AP2017009809A0 (en) | 2014-10-03 | 2017-03-31 | Ucb Biopharma Sprl | Fused pentacyclic imidazole derivatives |
| CN114057765A (zh) | 2015-02-02 | 2022-02-18 | 瓦洛健康股份有限公司 | 作为hdac抑制剂的3-芳基-4-酰氨基-二环[4,5,0]异羟肟酸 |
| AR103598A1 (es) | 2015-02-02 | 2017-05-24 | Forma Therapeutics Inc | Ácidos bicíclicos[4,6,0]hidroxámicos como inhibidores de hdac |
| CR20170572A (es) * | 2015-06-17 | 2018-03-20 | Pfizer | Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa |
| US10555935B2 (en) | 2016-06-17 | 2020-02-11 | Forma Therapeutics, Inc. | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL66835A (en) | 1981-09-24 | 1988-05-31 | Roussel Uclaf | 1,4-disubstituted(1,2,4)triazolo(4,3-alpha)quinazolin-5(4h)-one derivatives and their salts,their preparation and pharmaceutical compositions containing them |
| DE3601731A1 (de) | 1986-01-22 | 1987-07-23 | Merck Patent Gmbh | Pyrimidinderivate |
| US4808587A (en) | 1986-04-16 | 1989-02-28 | Nippon Zoki Pharmaceutical Co., Ltd. | 5-substituted pyrido[2,3-d]pyrimidine-2,4-diones |
| DE3738844A1 (de) | 1987-11-16 | 1989-05-24 | Merck Patent Gmbh | Analgetikum |
| DE4035479A1 (de) | 1990-11-08 | 1992-05-14 | Basf Ag | Substituierte pyrido (2,3-d)pyrimidin-2,4(1h,3h)-dione |
| ES2137113B1 (es) * | 1997-07-29 | 2000-09-16 | Almirall Prodesfarma Sa | Nuevos derivados de triazolo-piridazinas heterociclicos. |
| JP2000119272A (ja) | 1998-10-15 | 2000-04-25 | Nippon Zoki Pharmaceut Co Ltd | 新規７−アミノピリド〔２，３−ｄ〕ピリミジン誘導体 |
| FR2792938B1 (fr) * | 1999-04-28 | 2001-07-06 | Warner Lambert Co | NOUVELLES 1-AMINO TRIAZOLO [4,3-a] QUINAZOLINE-5-ONES INHIBITRICES DE PHOSPHODIESTERASES IV |
| TWI243055B (en) | 2000-04-13 | 2005-11-11 | Nippon Zoki Pharmaceutical Co | Pharmaceutical composition for use in treatment of dermatitis |
-
2001
- 2001-11-26 FR FR0115249A patent/FR2832711B1/fr not_active Expired - Fee Related
-
2002
- 2002-11-04 TW TW091132503A patent/TW200300344A/zh unknown
- 2002-11-22 SV SV2002001410A patent/SV2003001410A/es not_active Application Discontinuation
- 2002-11-22 PE PE2002001123A patent/PE20030664A1/es not_active Application Discontinuation
- 2002-11-22 US US10/303,103 patent/US6787554B2/en not_active Expired - Fee Related
- 2002-11-22 UY UY27546A patent/UY27546A1/es not_active Application Discontinuation
- 2002-11-22 PA PA20028558301A patent/PA8558301A1/es unknown
- 2002-11-25 AR ARP020104520A patent/AR038003A1/es not_active Application Discontinuation
- 2002-11-25 MX MXPA04004429A patent/MXPA04004429A/es not_active Application Discontinuation
- 2002-11-25 EP EP02796623A patent/EP1451190A1/fr not_active Withdrawn
- 2002-11-25 BR BR0214439-5A patent/BR0214439A/pt not_active IP Right Cessation
- 2002-11-25 WO PCT/EP2002/014184 patent/WO2003045951A1/fr not_active Ceased
- 2002-11-25 CA CA002468071A patent/CA2468071A1/fr not_active Abandoned
- 2002-11-25 AU AU2002361407A patent/AU2002361407A1/en not_active Abandoned
- 2002-11-25 JP JP2003547401A patent/JP2005529843A/ja active Pending
- 2002-11-26 HN HN2002000327A patent/HN2002000327A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW200300344A (en) | 2003-06-01 |
| US20030187257A1 (en) | 2003-10-02 |
| FR2832711B1 (fr) | 2004-01-30 |
| US6787554B2 (en) | 2004-09-07 |
| CA2468071A1 (fr) | 2003-06-05 |
| UY27546A1 (es) | 2003-06-30 |
| HN2002000327A (es) | 2003-06-09 |
| AU2002361407A1 (en) | 2003-06-10 |
| SV2003001410A (es) | 2003-04-03 |
| PA8558301A1 (es) | 2003-09-17 |
| FR2832711A1 (fr) | 2003-05-30 |
| EP1451190A1 (fr) | 2004-09-01 |
| BR0214439A (pt) | 2004-11-03 |
| JP2005529843A (ja) | 2005-10-06 |
| PE20030664A1 (es) | 2003-08-28 |
| WO2003045951A1 (fr) | 2003-06-05 |
| MXPA04004429A (es) | 2005-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR038003A1 (es) | Compuesto de triazolo[4,3-a]pirido(2,3-d)pirimidin-5-ona, composiciones que lo contienen, metodo de preparacion y su uso | |
| RU2441869C2 (ru) | Противовирусные соединения | |
| AR059620A1 (es) | Moduladores pirrolo - piridinicos de quinasas | |
| HUP0203895A2 (hu) | Szubsztituált azaindolok és ilyen vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk | |
| KR960703852A (ko) | 이환상 테트라하이드로 피라졸로피리딘(bicyclic tetrahydro pyrazolopyridines) | |
| TW200738706A (en) | Pyrido-, pyrazo-and pyrimido-pyrimidine derivatives and their use as mTOR inhibitors | |
| NZ524475A (en) | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | |
| CO5261497A1 (es) | Gama-hidroxi-2-(fluoroalquilamino-carbonil)-1-piperazino pentanamidas y sus usos | |
| HUP0401711A2 (hu) | TNF-alfa N-heterociklusos inhibitorai és ezeket tartalmazó gyógyszerkészítmények | |
| AR023659A1 (es) | Un compuesto inhibidor de p38, una composicion farmaceutica que lo comprende y el uso de dicha composicion en el tratamiento y prevencion de estados patologicos | |
| DE60217114D1 (de) | Verbrückte bizyklische serinproteaseinhibitoren | |
| CY1105811T1 (el) | Ενωσεις ενισχυτη ταξολης | |
| AR043436A1 (es) | Tetrahidroisoquinolinas sustituidas para uso como moduladores 5-ht6 | |
| PE20060381A1 (es) | Analogos de dipeptidos inhibidores de la hepatitis c | |
| ECSP055815A (es) | Composición para el tratamiento de la infección por virus flaviviridae | |
| ECSP034534A (es) | Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7 | |
| DE60024471D1 (de) | Benzopyran derivate | |
| PE20242099A1 (es) | Compuestos de piridotriazina sustituidos y usos de estos | |
| ES2194683T3 (es) | Nuevos derivados siliciados de bencimidazol-benzazoles n-sustituidos o de bezofuranil-benzazoles filtros; composiciones cosmeticas fotoprotectoras que los contienen y utilizacion. | |
| AR069127A1 (es) | Antagonistas del receptor de procineticina 1 que contienen amino-heteroarilo | |
| CO5601021A2 (es) | Derivados de quinazolinona, composiciones farmaceuticas que los contienen y su proceso de preparacion y su uso como antagonistas cb | |
| BRPI0417007A (pt) | agentes antivirais de diazaindol-dicarbonil-piperazinila | |
| KR940014397A (ko) | 비사이클릭 아민 유도체 | |
| WO2003018549A3 (en) | Bicyclic compounds as inhibitors of chemokine binding to us28 | |
| EA200100090A3 (ru) | Новые пиперидин-4-сульфонамидные производные, способ их получения и содержащие их фармацевтические композиции |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |